Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006

European Journal of Cancer

Volumn 43, Issue 2, 2007, Pages 238-257

  Liebens, Fabienne Patricia ^a   Carly, Birgit ^a   Pastijn, Ann ^a   Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adjuvant treatment; BRCA; Breast cancer; Breast conservation treatment; Mastectomy; Prophylactic strategy; Recurrence; Risk reduction; Systematic review

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFOUNDING VARIABLE; GENE MUTATION; HUMAN; MASTECTOMY; ONCOGENE; OUTCOMES RESEARCH; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846306403     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.07.019     Document Type: Article

References (115)

1. Emery J., Lucassen A., and Murphy M. Common hereditary cancers and implications for primary care. Lancet 358 (2001) 56-63
2. McClain M.R., Palomaki G.E., Nathanson K.L., and Haddow J.E. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7 (2005) 28-33
3. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., and Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365-1372
4. Easton D.F., Bishop D.T., Ford D., and Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52 (1993) 678-701
5. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
6. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130
7. Verhoog L.C., van den Ouweland A.M.W., Berns E., et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 37 (2001) 2082-2090
8. Górski B., Jakubowska A., Huzarski T., et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. International Journal of Cancer 110 (2004) 683-686
9. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 (2004) 665-676
10. Speit G., and Trenz K. Chromosomal mutagen sensitivity associated with mutations in BRCA genes. Cytogenet Genome Res 104 (2004) 325-332
11. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., and Harkinet D.P. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96 (2004) 1659-1668
12. Nelson H.D., Huffman L.H., Fu R., and Harris E.L. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143 (2005) 355-361
13. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
14. Eisinger F, Bressac B, Castaigne D, et al. Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004). Bull Cancer 2004;91:219-37.
15. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991;265:391-395.
16. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
17. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
18. Morris A.D., Morris R.D., Wilson J.F., et al. Breast-conserving therapy vs. mastectomy in early-stage breast cancer: A meta-analysis of 10-year survival. Cancer J Sci Am 3 (1997) 6-12
19. de Bock G.H., van der Hage J.A., Putter H., Bonnema J., Bartelink H., and van de Velde C.J. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42 (2006) 351-356
20. Schwartz M.D., Lerman C., Brogan B., et al. Impact of BRCA1/BRCA2 counselling and testing in newly diagnosed breast cancer patients. J Clin Oncol 22 (2004) 1823-1829
21. Weitzel J.N., McCaffrey S.M., Nedelcu, MacDonald D.J., Blazer K.R., and Cullinane C.A. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138 (2003) 1323-1328
22. Stolier A.J., Fuhrman G.M., Mauterer, Bolton J.S., and Superneau D.W. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Breast J. 10 (2004) 475-480
23. Peshkin B.N., Isaacs C., Willey S., and Schwartz M.D. In Reply. J Clin Oncol 23 (2005) 3166-3167
24. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
25. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792
26. Clark G.M. Prognostic and predictive factors. In: Harris J.R., Lippman M.E., Morrow M., and Hellman S. (Eds). Diseases of the Breast (1996), Lippincott-Raven, Philadelphia, PA 461-485
27. Andrulis I.L., Bull S.B., Blackstein M.E., et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16 (1998) 1340-1349
28. Lakhani S.R., van de Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
29. Walsh T., Casadei S., Coats K.H., et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama 295 (2006) 1379-1388
30. Meade M.O., and Richardson W.S. Selecting and appraising studies for a systematic review. Ann Intern Med 127 (1997) 531-537
31. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 127 (1997) 380-387
32. Foulkes W.D., Chappuis P.O., Wong N., et al. Primary node negative breast cancer in BRCAI mutation carriers has a poor outcome. Ann Oncol 11 (2000) 307-313
33. Alpert T.E., Kuerer H.M., Arthur D.W., Lannin D.R., and Haffty B.G. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys 63 (2005) 845-851
34. Loman N., Johannsson O., Bendahl P., et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 36 (2000) 1365-1373
35. Ansquer Y., Gautier C., Fourquet A., Asselain B., and Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Lancet 352 (1998) 541
36. Lee J.S., Wacholder S., Struewing J.P., et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 91 (1999) 259-263
37. Veronesi A., de Giacomi C., Magri M.D., et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 5 (2005) 70
38. Kim S., Rimm D., Carter D., et al. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. Breast J 9 (2003) 167-174
39. Moller P., Borg A., Evans D.G., et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101 (2002) 555-559
40. Eerola H., Vahteristo P., Sarantaus L., et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 93 (2001) 368-372
41. Goode E.L., Dunning A.M., Kuschel B., et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62 (2002) 3052-3057
42. Wagner T., Möslinger R., Muhr D., et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics. Int J Cancer 77 (1998) 354-360
43. Porter D.E., Cohen B.B., Wallace M.R., et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81 (1994) 1512-1515
44. Verhoog L., Brekelmans C., Seynaeve C., et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351 (1998) 316-321
45. Robson M., Levin D., Federici M., et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91 (1999) 2112-2117
46. Foulkes W.D., Wong N., Brunet J.S., et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3 (1997) 2465-2469
47. Chabner E., Nixon A., Gelman R., et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 16 (1998) 2045-2051
48. Israeli D., Tartter P.I., Brower S.T., Mizrachy B., and Bratton J. The significance of family history for patients with carcinoma of the breast. J Am Coll Surg 179 (1994) 29-32
49. Haas J.A., Schultz D.J., Peterson M.E., and Solin L.J. An analysis of age and family history on outcome after breast-conservation treatment: the University of Pennsylvania experience. Cancer J Sci Am 4 (1998) 308-315
50. Harrold E.V., Turner B.C., Matloff E.T., et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am 4 (1998) 302-307
51. Brekelmans C.T., Voogd A.C., Botke G., et al. Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Eur J Cancer 35 (1999) 620-626
52. Harris E.E., Schultz D.J., Peters C.A., et al. Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 48 (2000) 933-941
53. Vlastos G., Mirza N.Q., Meric F., et al. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9 (2002) 912-919
54. Marcus J.N., Watson P., Page D.L., et al. Hereditary breast cancer: pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 77 (1996) 697-709
55. Haffty B.G., and Lannin D. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?. Eur J Cancer 40 (2004) 1105-1108
56. Mincey B.A. Genetics and the management of women at high risk for breast cancer. Oncologist 8 (2003) 466-473
57. Nicoletto M.O., Donach M., De Nicolo A., et al. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treatment Reviews 27 (2001) 295-304
58. Alpert T.E., and Haffty B.G. Conservative management of breast cancer in BRCA1/2 mutation carriers. Clin Breast Cancer 5 (2004) 37-42
59. Narod S.A., and Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 23 (2005) 1656-1663
60. Newman L.A., and Kuerer H.M. Advances in breast conservation therapy. J Clin Oncol 23 (2005) 1685-1697
61. Newman L.A., Kuerer H.M., Hunt K.K., et al. Educational review: Role of the surgeon in hereditary breast cancer. Ann Surg Oncol 8 (2001) 368-378
62. Pierce L.J., Strawderman M., Narod S.A., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18 (2000) 3360-3369
63. Pierce L.J., Levin A.M., Rebbeck T.R., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24 (2006) 2437-2443
64. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17 (2006) 391-400
65. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17 (1999) 3396-3402
66. Seynaeve C., Verhoog L.C., van de Bosch L.M.C., et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40 (2004) 1150-1158
67. Robson M., Chappuis P., Satagopan J., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6 (2004) 8-17
68. Goffin J.R., Chappuis P.O., Begin L.R., et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow-up data. Cancer 97 (2003) 527-536
69. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol 16 (1998) 1642-1649
70. Robson M., Svahn T., McCormick B., et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2. Cancer 103 (2005) 44-51
71. Stoppa-Lyonnet D., Ansquer Y., Dreyfus H., et al. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 18 (2000) 4053-4059
72. Kirova Y., Stoppa-Lyonnet D., Savignoni A., et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41 (2005) 2304-2311
73. Delaloge S., Kloos I., Ariane D., et al. Young age is the major predictor of local relapse among conservatively treated BRCA1-, BRCA2-, or non BRCA-linked hereditary breast cancer (BC). Proc Am Soc Clin Oncol 22 (2003) 11 abstr 41
74. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359 (2002) 1471-1477
75. Turner B., Harrold E., Matloff E., et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17 (1999) 3017-3024
76. Chappuis P., Kapusta L., Begin L., et al. Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 18 (2000) 4045-4052
77. El-Tamer M., Russo D., Troxel A., et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11 (2004) 157-164
78. Bremer M, Doerk T, Sohn C, et al. Local relapse after postoperative radiotherapy in patients with bilateral breast cancer by BRCA1/2 status. Proceedings Asco, 2003. abstract 42.
79. Metcalfe K., Lynch H., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22 (2004) 2328-2335
80. Eccles D., Simmonds P., Goddard J., et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer 1 (2001) 65-72
81. Johannsson O., Ranstam J., Borg A., et al. Survival of BRCA1 breast and ovarian cancer patients: a population- based study from southern Sweden. J Clin Oncol 16 (1998) 397-404
82. Gaffney D., Brohet R., Lewis C., et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47 (1998) 129-136
83. Phillips K.A., Andrulis I.L., and Goodwin P.J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?. J Clin Oncol 17 (1999) 3653-3663
84. Wacholder S. Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst 96 (2004) 1204-1207
85. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin Cancer Res 10 (2004) 2029-2034
86. Eisinger F., Stoppa-Lyonnet D., Longy M., et al. Germline mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56 (1996) 471-474
87. Sobol H., Stoppa-Lyonnet D., Bressac-de-Paillerets B., et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 56 (1996) 3216-3219
88. Thompson D., and Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2001) 410-419
89. Sevilla C., Moatti J.P., Julian-Reynier C., et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 10 (2002) 599-606
90. Peshkin B.N., DeMarco T.A., Brogan B.M., Lerman C., and Isaacs C. BRCA1/2 testing: Complex themes in result interpretation. J Clin Oncol 19 (2001) 2555-2565
91. Haffty B.G., Silber A., Matloff E., Chung J., and Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 43 (2006) s133-s137
92. Pal T., Permuth-Wey J., Holtje T., and Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev 13 (2004) 1794-1799
93. Baeyens A., Thierens H., Claes K., Poppe B., de Ridder L., and Vral A. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Biol. 80 (2004) 745-756
94. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study. J Clin Oncol 2006. Epub ahead of print.
95. Hellman S. The key and the lamppost. J Clin Oncol 17 (1999) 3007-3008
96. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 (2001) 1633-1637
97. Schrag D., Kuntz K.M., Garber J.E., and Weeks J.C. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336 (1997) 1465-1471
98. Hartmann L.C., Degnim A., and Schaid D.J. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol 22 (2004) 981-983
99. Frost M.H., Slezak J.M., Tran N.V., et al. Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23 (2005) 7849-7856
100. Stefanek M., Hartmann L., and Nelson W. Risk-reduction mastectomy: Clinical issues and research needs. J Natl Cancer Inst 93 (2001) 1297-1306
101. Julian-Reynier C.M., Bouchard L.J., Evans D.G., et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92 (2001) 959-968
102. Eisinger F., Julian-Reynier C., Sobol H., et al. Acceptability of prophylactic mastectomy in cancer-prone women. JAMA 283 (2000) 202-203
103. Meijers-Heijboer H., Brekelmans C., Menke-Pluymers M., et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21 (2003) 1675-1681
104. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
105. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 346 (2002) 1660-1662
106. Domchek S., Friebel T.M., Neuhausen S.L., et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7 (2006) 223-229
107. Kauff N., Satagopan J., Robson M., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
108. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118 (2006) 2281-2284
109. Warner E., Plewes D., Hill K., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (2004) 1317-1325
110. Kuhl C., Schrading S., Leutner C., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23 (2005) 8469-8476
111. Kriege M., Brekelmans C., Boetes C., et al. The magnetic resonance imaging screening study group, efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (2004) 427-437
112. Leach M.O. MARIBS study group. Lancet 365 (2005) 1769-1778
113. Haber D. Breast cancer in carriers of BRCA1 and BRCA2 mutations: Tackling a molecular and clinical conundrum. J Clin Oncol 17 (1999) 3367-3370
114. Travis L., Rabkin C., Brown L., et al. Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 98 (2006) 15-25
115. Tambor E.S., Bernhardt B.A., Geller G., Helzlsouer K.J., Doksum T., and Holtzman N.A. Should women at increased risk for breast and ovarian cancer be randomized to prophylactic surgery?. An ethical and empirical assessment. J Womens Health Gend Based Med 9 (2000) 223-233